GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sucampo Pharmaceuticals Inc (NAS:SCMP) » Definitions » Shiller PE Ratio

Sucampo Pharmaceuticals (Sucampo Pharmaceuticals) Shiller PE Ratio : (As of Apr. 26, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Sucampo Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Sucampo Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Sucampo Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sucampo Pharmaceuticals Shiller PE Ratio Chart

Sucampo Pharmaceuticals Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 97.84 58.94 53.64

Sucampo Pharmaceuticals Quarterly Data
Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 52.73 53.64 41.62 - -

Competitive Comparison of Sucampo Pharmaceuticals's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Sucampo Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sucampo Pharmaceuticals's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sucampo Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Sucampo Pharmaceuticals's Shiller PE Ratio falls into.



Sucampo Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Sucampo Pharmaceuticals's E10 for the quarter that ended in Sep. 2017 is calculated as:

For example, Sucampo Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2017 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2017 (Change)*Current CPI (Sep. 2017)
=0.19/104.1356*104.1356
=0.190

Current CPI (Sep. 2017) = 104.1356.

Sucampo Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200712 -0.030 88.616 -0.035
200803 0.010 90.090 0.012
200806 0.710 92.320 0.801
200809 -0.060 92.307 -0.068
200812 -0.080 88.697 -0.094
200903 -0.040 89.744 -0.046
200906 -0.010 91.003 -0.011
200909 0.000 91.120 0.000
200912 0.160 91.111 0.183
201003 0.040 91.821 0.045
201006 0.000 91.962 0.000
201009 0.050 92.162 0.056
201012 -0.160 92.474 -0.180
201103 -0.170 94.283 -0.188
201106 -0.220 95.235 -0.241
201109 -0.100 95.727 -0.109
201112 0.070 95.213 0.077
201203 -0.050 96.783 -0.054
201206 -0.020 96.819 -0.022
201209 -0.140 97.633 -0.149
201212 0.330 96.871 0.355
201303 -0.080 98.209 -0.085
201306 0.150 98.518 0.159
201309 0.040 98.790 0.042
201312 0.050 98.326 0.053
201403 0.020 99.695 0.021
201406 0.040 100.560 0.041
201409 0.030 100.428 0.031
201412 0.200 99.070 0.210
201503 0.140 99.621 0.146
201506 0.210 100.684 0.217
201509 0.160 100.392 0.166
201512 0.220 99.792 0.230
201603 -0.100 100.470 -0.104
201606 -0.020 101.688 -0.020
201609 0.190 101.861 0.194
201612 0.350 101.863 0.358
201703 0.100 102.862 0.101
201706 -3.920 103.349 -3.950
201709 0.190 104.136 0.190

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sucampo Pharmaceuticals  (NAS:SCMP) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Sucampo Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Sucampo Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sucampo Pharmaceuticals (Sucampo Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Sucampo Pharmaceuticals Inc is a part of the healthcare sector in the United States. As a global pharmaceutical company, it commercializes drugs for the treatment of various gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It currently generates revenue mainly from product royalties, product sales, upfront and milestone payments, and reimbursements for development activities.
Executives
Peter Greenleaf officer: Chief Executive Officer ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Maureen Oconnell director
Karen L. Smith director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Jones W. Bryan officer: Sr. Vice Pres., BD & Licensing C/O SUPERNUS PHARMACEUTICALS, INC., 1550 EAST GUDE DRIVE, ROCKVILLE MD 20850
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Timothy P Walbert director 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Peter A Kiener officer: Chief Science Officer 40 GUEST STREET, BOSTON MA 02135
John Johnson director DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Peter P. Pfreundschuh officer: CFO C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Paul R Edick director C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010
Thomas J Knapp other: Former Officer 4640 SW MACADAM AVE., SUITE 270, PORTLAND OR 97239
William Ashton director C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Timothy I Maudlin director 18739 VOGEL FARM TRAIL, EDEN PRAIRIE MN 55347
Nantahala Capital Management, Llc 10 percent owner 130 MAIN ST., 2ND FLOOR, NEW CANAAN CT 06840
Mariam E Morris officer: Chief Acctg. Officer, Treas. C/O SUCAMPO PHARMACEUTICALS, 4520 EAST-WEST HIGHWAY, SUITE 300, BETHESDA MD 20814

Sucampo Pharmaceuticals (Sucampo Pharmaceuticals) Headlines